Abstract
The medical community and the public have been buffeted by a steady stream of news linking the use of widely prescribed medications with serious health risks. The latest in this barrage of unsettling reports is an article by Park-Wyllie et al. that appears elsewhere in this issue of the Journal 1 regarding the association of the fluoroquinolone gatifloxacin with dysglycemia.The authors describe the findings of two population-based, nested case–control studies involving outpatients 66 years of age or older who had received treatment with various broad-spectrum antibiotics. The first study demonstrated a substantial increase in the risk of emergency department treatment . . .

This publication has 7 references indexed in Scilit: